Evaluation of the safety and efficacy of Continuous Dopaminergic Stimulation by intracerebroventricular administration of anaerobically conserved dopamine in Parkinson's disease at the motor fluctuation stage: Single-center pilot study

2024-517566-42-00 Phase I and Phase II (Integrated) - First administration to humans Ended

End 2 Oct 2025 · Status Ended · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - First administration to humans
Status Ended
Participants planned 12
Countries 1
Sites 1

Parkinson's disease

Key facts

Sponsor
Centre Hospitalier Universitaire De Lille, InBrain Pharma
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
completed 2 Oct 2025
Decision date (initial)
2024-11-14
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-517566-42-00
EudraCT number
2020-000155-12
ClinicalTrials.gov
NCT04332276

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Parkinson's disease

VersionLevelCodeTermSystem organ class
20.0 PT 10061536 Parkinson's disease 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Hospitalier Universitaire De Lille

Sponsor organisation
Centre Hospitalier Universitaire De Lille
Address
2 Avenue Oscar Lambret, Cs 70001 Cs 70001
City
Lille Cedex
Postcode
59037
Country
France

Scientific contact point

Organisation
Centre Hospitalier Universitaire De Lille
Contact name
David DEVOS

Public contact point

Organisation
Centre Hospitalier Universitaire De Lille
Contact name
Brigitte COURTOIS

InBrain Pharma

Sponsor organisation
InBrain Pharma
Address
Parc Eurasante Ouest, 70 Rue Du Docteur Yersin 70 Rue Du Docteur Yersin
City
Loos
Postcode
59120
Country
France

Scientific contact point

Organisation
InBrain Pharma
Contact name
Véronique FOUTEL

Public contact point

Organisation
InBrain Pharma
Contact name
Véronique FOUTEL

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 12 1
Rest of world 0

Investigational sites

France

1 site · Ended
Centre Hospitalier Universitaire De Lille
Neurology, 2 Avenue Oscar Lambret, Cs 70001, Lille Cedex

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-08 France Acceptable
2024-11-14
2024-11-14
2 SUBSTANTIAL MODIFICATION SM-2 2025-04-02 France Acceptable
2025-05-16
2025-05-16